Growing Shareholder Value

Press Releases

Planet abiomed Inc.
Nov 01,2012

Abiomed Announces Revenue of $37.4 Million, Up 27% and Worldwide Impella(R) Revenue Growth of 32%

  • Record GAAP Profitability of $5.5 Million or $0.13 Per Diluted Share

DANVERS, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2013 revenue of $37.4 million, up 27% compared to revenue of $29.5 million in the same period of fiscal 2012, and GAAP net income of $5.5 million or $0.13 per diluted share in the second quarter of fiscal 2013, compared to GAAP net income of $0.6 million or $0.02 per diluted share in the same period of fiscal 2012.

Recent financial and operating highlights include the following:

  • Fiscal second quarter worldwide Impella revenue totaled $32.8 million, up 32% compared to revenue of $24.8 million during the same period of the prior year. U.S. Impella revenue grew 33% to $30.8 million from $23.1 million in the prior year.
  • As targeted, an additional 30 hospitals purchased Impella 2.5 during the quarter, bringing the total to 695 U.S. Impella customer sites.
  • Gross margin rate for the second quarter of fiscal 2013 was 80.8% compared to 81.2% in the second quarter of fiscal 2012.
  • Non-GAAP net income for the second quarter of fiscal 2013, which is described later in this press release, was $8.4 million or $0.20 per diluted share, compared to $3.4 million or $0.09 per diluted share in the second quarter of fiscal 2012.
  • Cash, cash equivalents and short-term marketable securities totaled $89.0 million as of September 30, 2012, an increase of $7.8 million from June 30, 2012 and an increase of $11.8 million from March 31, 2012.
  • On October 26, 2012, Abiomed was informed that the United States Attorney's Office for the District of Columbia is conducting an investigation that is focused on the Company's marketing and labeling of the Impella 2.5. On October, 31, 2012, Abiomed accepted service of a Health Insurance Portability and Accountability Act administrative subpoena related to this investigation. The subpoena seeks documents related to the Impella 2.5 and we understand the investigation focuses primarily on marketing and labeling issues. Abiomed is in the process of responding to the subpoena and intends to cooperate fully.
  • In September 2012, the PROTECT II study was published in Circulation, the journal of the American Heart Association. The article, titled "A Prospective Randomized Clinical Trial of Hemodynamic Support with Impella 2.5 versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention: the PROTECT II Study," was published online on August 30, 2012 and in print on October 2, 2012.
  • In September, the American Medical Association confirmed three new Category I Current Procedural Terminology (CPT®) codes for Impella percutaneous technologies, effective January 1, 2013. In November 2012, SCAI, ACC, and HRS will provide more details on the valuation and payment of the specific codes. 
  • Abiomed received 510(k) clearance in September from the U.S. Food and Drug Administration for Impella CP™, a new percutaneous catheter-based Impella device.  The increased flow is delivered on the same console platform, 9 French catheter, and introducer as the Impella 2.5. The Impella CP is available under a controlled launch with top U.S. heart hospitals.
  • Abiomed believes that the Food and Drug Administration (FDA) 515 Program Initiative will hold an Advisory Panel in early December 2012 to review the classification determination of "intra-aortic balloon and control systems," and "nonroller-type cardiopulmonary bypass blood pumps," which includes Impella products. Since this has not been formally announced by the FDA, this estimated timing is subject to change.
  • At the Transcatheter Cardiovascular Therapeutics 2012 meeting in October, a clinical update on the Symphony program was presented. The second successful Symphony implant patient received 28 days of continuous therapy at the McGill University Health Centre (MUHC) in Montreal, Canada. Symphony also received Agence Nationale de Sécurité due Médicament (ANSM) approval in France, enabling its use in clinical trials. The Symphony is not cleared for sale or use in the United States and is currently being used in clinical investigations in Canada and France.

"Our strong execution led to this quarter's record profitability and cash flow. Going forward, we will continue to focus on our patients," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. 

The Company is maintaining its fiscal year 2013 revenue guidance in a range of $155 million to $157 million, representing annual growth of 23% to 24%, with worldwide Impella revenues forecast to grow greater than 30%.

The Company will host a conference call to discuss the second quarter fiscal year 2013 results on Thursday, November 1, 2012, at 8:00 a.m. ET with Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer; and Susan V. Lisa, Senior Director of Investor Relations and Corporate Development.

To listen to the call live, please tune into the webcast via or dial (866) 628-3070; the international number is (224) 357-2384. A replay of this conference call will be available beginning at 11 a.m. ET on November 1, 2012 through 11:59 p.m. ET on November 7, 2012. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 50239953.


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit:


In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures of net income, net income per share, net loss and net loss per share, in each case excluding, where appropriate, stock-based compensation, intangibles amortization and other costs, expenses or income, all as further detailed in the financial tables accompanying this earnings announcement, which management believes are useful supplemental information to management and investors regarding the performance of the Company's business operations, provide a greater transparency with respect to key metrics used by management in its decision making, facilitate comparisons of results for current periods and assist in analyzing future trends. We believe that the inclusion of these non-GAAP financial measures in this earnings announcement helps investors to gain a meaningful understanding of our core operating results and future prospects, and can also help investors who wish to make comparisons between us and other companies on both a GAAP and a non-GAAP basis, particularly with respect to stock based compensation expenses. The non-GAAP financial measures included in this earnings announcement are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies. Although certain non-GAAP financial measures used in this release exclude the accounting treatment of stock based compensation expense and other items outlined in this release, these non-GAAP measures should not be relied upon independently, as they ignore the contribution to our operating results that is generated by the incentive and compensation effects of the underlying stock based compensation programs.


This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share data)
 September 30, 2012March 31, 2012
Current assets:    
Cash and cash equivalents  $4,497  $5,990
Short-term marketable securities  84,484  71,233
Accounts receivable, net   18,801  20,458
Inventories   14,461  11,142
Prepaid expenses and other current assets  1,791  1,716
Total current assets  124,034  110,539
Property and equipment, net  6,268  6,378
Intangible assets, net  --   115
Goodwill  35,512  36,846
Other long-term assets  32  33
Total assets  $165,846  $153,911
Current liabilities:    
Accounts payable  $5,211  $6,910
Accrued expenses  11,596  12,480
Deferred revenue  2,896  3,025
Total current liabilities  19,703  22,415
Long-term deferred tax liability  5,117  4,799
Other long-term liabilities  354  400
Total liabilities  25,174  27,614
Commitments and contingencies    
Stockholders' equity:    
Class B Preferred Stock, $.01 par value  --   -- 
Authorized - 1,000,000 shares; Issued and outstanding - none  
Common stock, $.01 par value  397  393
Authorized - 100,000,000 shares;     
Issued - 39,717,551 shares at September 30, 2012 and 39,323,708 shares at March 31, 2012;  
Outstanding - 39,655,207 shares at September 30, 2012 and 39,272,754 shares at March 31, 2012  
Additional paid in capital  409,519  401,771
Accumulated deficit  (264,687)  (273,275)
Treasury stock at cost - 62,344 shares at September 30, 2012 and 50,954 shares at March 31, 2012  (1,065)  (827)
Accumulated other comprehensive loss  (3,492)  (1,765)
Total stockholders' equity  140,672  126,297
Total liabilities and stockholders' equity  $165,846  $153,911
Abiomed, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except share data)
 Three Months Ended Six Months Ended  
 September 30,September 30,
Product revenue  $37,319  $29,151  $75,966  $56,317
Funded research and development  98  327  234  516
   37,417  29,478  76,200  56,833
Costs and expenses:        
Cost of product revenue   7,194  5,551  14,640  11,442
Research and development   5,854  6,459  12,566  13,783
Selling, general and administrative   18,437  16,323  39,390  34,499
Amortization of intangible assets  --   379  111  764
   31,485  28,712  66,707  60,488
Income (loss) from operations  5,932  766  9,493  (3,655)
Other (expense) income:        
Investment income (expense), net  1  (6)  (1)  (2)
Other (expense) income, net  (9)  66  (13)  (15)
   (8)  60  (14)  (17)
Income (loss) before income tax provision  5,924  826  9,479  (3,672)
Income tax provision  455  225  891  321
Net income (loss)  $5,469  $601  $8,588  $(3,993)
Basic net income (loss) per share  $0.14  $0.02  $0.22  $(0.10)
Basic weighted average shares outstanding  39,431  38,256  39,288  38,081
Diluted net income (loss) per share  $0.13  $0.02  $0.21  $(0.10)
Diluted weighted average shares outstanding  41,722  39,366  41,645  38,081
Abiomed, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP Net Income (Loss)
(in thousands, except for per share data)
 Three Months EndedSix Months Ended
 September 30, September 30, 
Net income (loss) on a GAAP basis  $ 5,469  $ 601  $ 8,588  $ (3,993)
Share-based compensation expense:        
 - Cost of product revenue  101  73  247  149
 - Research & development  435  372  998  872
 - Selling, general and administrative  1,748  1,354  3,718  3,110
Depreciation expense  649  580  1,258  1,241
Amortization of intangible assets  --  379  111  764
Income tax effect of non-GAAP adjustments  --  --  --  --
Net income on a non-GAAP basis  $ 8,402  $ 3,359  $ 14,920  $ 2,143
Net Income (Loss) Per Share Reconciliation
(in thousands, except for per share data)
 Three Months EndedSix Months Ended
 September 30, September 30, 
Net income (loss) per diluted share on a GAAP basis  $ 0.13  $ 0.02  $ 0.21  $ (0.10)
Share-based compensation expense:        
 - Cost of product revenue  --   --   0.01  0.01
 - Research & development  0.01 0.01  0.02 0.02
 - Selling, general and administrative  0.04 0.04  0.09 0.08
Depreciation expense  0.02  0.01  0.03  0.03
Amortization of intangible assets  --   0.01  --   0.02
Income tax effect of non-GAAP adjustments  --   --   --   -- 
Net income per diluted share on a non-GAAP basis  $ 0.20  $ 0.09  $ 0.36  $ 0.06
Shares used in calculation of net income (loss) per diluted share 41,722  39,366 41,645  38,081
CONTACT: Susie Lisa, CFA

         Senior Director, Investor Relations and Corporate Development



         Aimee Maillett

         Corporate Communications Manager